Bristol Myers Squibb (BMY) Other financing activities (2009 - 2022)

Bristol Myers Squibb (BMY) has 14 years of Other financing activities data on file, last reported at $179.0 million in Q4 2022.

• Other financing activities for Q4 2022 came in at $179.0 million, up 6066.67% year-over-year; the trailing twelve-month figure through Dec 2022 was $984.0 million (up 53.51% YoY), and the FY2023 annual result was $27.0 million, down 97.26% from the prior year.
• Other financing activities advanced to $179.0 million in Q4 2022 per BMY's latest filing, from $53.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $419.0 million in Q2 2022 and troughed at -$58.0 million in Q1 2018.
• A 5-year average of $103.0 million and a median of $35.5 million in 2020 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2019 and 2020: Other financing activities plunged 1400.0% in 2019, then jumped 17200.0% in 2020.
• A 5-year view of Other financing activities shows it stood at $1.0 million in 2018, then sank by 1400.0% to -$13.0 million in 2019, then surged by 2230.77% to $277.0 million in 2020, then slumped by 101.08% to -$3.0 million in 2021, then soared by 6066.67% to $179.0 million in 2022.
• Business Quant data shows BMY's Other financing activities at $179.0 million in Q4 2022, $53.0 million in Q3 2022, and $419.0 million in Q2 2022.